Goldman Sachs
AMLX icon

Goldman Sachs’s Amylyx Pharmaceuticals AMLX Stock Holding History

Goldman Sachs’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.3M Buy
2,858,239
+232,248
+9% +$3.59M ﹤0.01% 1780
2026
Q1 		$36.5M Buy
2,625,991
+12,770
+0.5% +$180K ﹤0.01% 1838
2025
Q4 		$31.6M Buy
2,613,221
+602,588
+30% +$8.18M ﹤0.01% 1928
2025
Q3 		$27.3M Buy
2,010,633
+712,651
+55% +$6.71M ﹤0.01% 1953
2025
Q2 		$8.32M Sell
1,297,982
-704,979
-35% -$3.43M ﹤0.01% 2929
2025
Q1 		$7.09M Buy
2,002,961
+143,065
+8% +$509K ﹤0.01% 3017
2024
Q4 		$7.03M Buy
1,859,896
+246,033
+15% +$1.16M ﹤0.01% 3119
2024
Q3 		$5.23M Sell
1,613,863
-996,557
-38% -$2.24M ﹤0.01% 3310
2024
Q2 		$4.96M Sell
2,610,420
-332,766
-11% -$645K ﹤0.01% 3161
2024
Q1 		$8.36M Buy
2,943,186
+1,686,325
+134% +$22.1M ﹤0.01% 2640
2023
Q4 		$18.5M Buy
1,256,861
+69,733
+6% +$1.07M ﹤0.01% 1977
2023
Q3 		$21.7M Sell
1,187,128
-163,350
-12% -$3.45M ﹤0.01% 1730
2023
Q2 		$29.1M Sell
1,350,478
-15,694
-1% -$424K 0.01% 1533
2023
Q1 		$40.1M Buy
1,366,172
+329,902
+32% +$11.5M 0.01% 1227
2022
Q4 		$38.3M Buy
1,036,270
+656,871
+173% +$23.3M 0.01% 1389
2022
Q3 		$10.7M Buy
+379,399
New +$9.47M ﹤0.01% 2445

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs's AMLX Position: Q2 2026 in Review

Goldman Sachs increased its Amylyx Pharmaceuticals (AMLX) stake by 8.8% in Q2 2026, buying an estimated $3.59M and bringing the position to 2,858,239 shares worth $51.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1780.

Goldman Sachs first reported a position in AMLX in Q3 2022 and has held it in 16 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Goldman Sachs held 2,858,239 shares of Amylyx Pharmaceuticals worth $51.3M as of Q2 2026.
  • Goldman Sachs bought 232,248 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $3.59M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1780 holding.
  • Goldman Sachs first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.